232 related articles for article (PubMed ID: 22035516)
1. Pegloticase: in treatment-refractory chronic gout.
Lyseng-Williamson KA
Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
[TBL] [Abstract][Full Text] [Related]
2. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Mandell BF; Yeo AE; Lipsky PE
Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
[TBL] [Abstract][Full Text] [Related]
4. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
[TBL] [Abstract][Full Text] [Related]
5. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
[TBL] [Abstract][Full Text] [Related]
6. Pegloticase for chronic gout.
Anderson A; Singh JA
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366
[TBL] [Abstract][Full Text] [Related]
7. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
8. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL
J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805
[TBL] [Abstract][Full Text] [Related]
9. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
[TBL] [Abstract][Full Text] [Related]
10. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
[TBL] [Abstract][Full Text] [Related]
12. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
Johnson RJ; Choi HK; Yeo AE; Lipsky PE
Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
[TBL] [Abstract][Full Text] [Related]
13. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
[TBL] [Abstract][Full Text] [Related]
14. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
[TBL] [Abstract][Full Text] [Related]
15. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
Schlesinger N; Lipsky PE
Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
[TBL] [Abstract][Full Text] [Related]
16. Pegloticase and the patient with treatment-failure gout.
Dave AJ; Kelly VM; Krishnan E
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
[TBL] [Abstract][Full Text] [Related]
17. Pegloticase: a novel agent for treatment-refractory gout.
Shannon JA; Cole SW
Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
[TBL] [Abstract][Full Text] [Related]
18. Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.
Keenan RT; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2022 May; 40(5):1006-1010. PubMed ID: 35238750
[TBL] [Abstract][Full Text] [Related]
19. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
[TBL] [Abstract][Full Text] [Related]
20. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
